Beyond Human Rights Due Diligence: What Else Do We Need?

Retinitis Pigmentosa: WHAT ELSE WE CAN DO?

Retinitis pigmentosa (RP) represents a group of progressive hereditary diseases of the retina that lead to incurable blindness and affect two million people worldwide and principally characterized by progressive rod-dominant photoreceptor degeneration in the initial stage and eventual cone photoreceptor degeneration in later stages. RP has been known to be initiated by photoreceptor apoptosis a...

Artemisinin and Its Derivatives as a Repurposing Anticancer Agent: What Else Do We Need to Do?

Preclinical investigation and clinical experience have provided evidence on the potential anticancer effect of artemisinin and its derivatives (ARTs) in the recent two decades. The major mechanisms of action of ARTs may be due to toxic-free radicals generated by an endoperoxide moiety, cell cycle arrest, induction of apoptosis, and inhibition of tumor angiogenesis. It is very promising that ART...

What do we know? What do we need to know?

Clinical characteristics of elderly patients with heart failure: what else do we need to know?

Improving our forecasts for trachoma elimination: What else do we need to know?

The World Health Organization (WHO) has targeted trachoma for elimination as a public health concern by 2020. Mathematical modelling is used for a range of infectious diseases to assess the impact of different intervention strategies on the prevalence of infection or disease. Here we evaluate the performance of four different mechanistic mathematical models that could all realistically represen...